Zydus Lifesciences starts Phase IV clinical trials for novel drug 'Desidustat'

Zydus said Desidustat, sold under the Oxemia trademark, is a prescription drug approved in India for patients with CKD induced anemia, and can be taken only under the advice and guidance of a nephrologist or an internal medicine specialist.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/pAu52Lf